The UK government is seriously reconsidering its £330 million contract with Palantir for NHS data management. The deal, signed in late 2023, faces a potential early exit in 2027. This marks a rare public admission of doubts about a major tech partnership in healthcare.

Palantir’s Federated Data Platform was supposed to unify patient data across NHS England and improve clinical decisions. Instead, it has become a political lightning rod. Critics cite opaque procurement, US-based control over sensitive data, and growing concerns about security and ethics.

A parliamentary committee called the contract a “serious point of weakness” and urged the government to trigger the break clause in 2027. MPs worry about “vendor lock-in” and the risks of depending on a foreign AI supplier for the nation’s health infrastructure. The NHS’s cyber threat level has been raised to its highest, adding urgency.

Palantir pushes back, insisting its software only processes data under strict NHS instructions. The company denies any improper data access and warns against “ideologically motivated” calls to abandon the contract. But that argument is losing ground amid rising patient opt-outs and public distrust.

The government says it is reviewing the entire contract to secure “the right deal for Britain.” But unwinding a system embedded in NHS operations won’t be cheap or simple. Still, the debate signals a shift toward prioritizing domestic technology sovereignty and tighter data governance in public healthcare.

Why This Matters

The crux of the issue is control over health data—the new oil of the digital age. The NHS holds records on 65 million people, a treasure trove for AI research and public health planning. Handing this to a US firm with defense and intelligence links raises sovereignty alarms.

Lawmakers emphasize the need for transparent AI governance. They want independent audits, clear algorithms, and an exit plan that ensures data portability. The current contract offers no software ownership or improvements after subscription fees end. This locks the NHS into Palantir’s ecosystem without building internal capability.

Calls are growing for investing in UK-based alternatives and rebuilding digital infrastructure in-house. This would require major funding and talent acquisition. But the political appetite for such an overhaul is uncertain amid fiscal pressures.

The NHS controversy underscores a broader European unease about dependence on US tech giants in critical sectors. The stakes are high. Relying on a single foreign provider for sensitive data and AI tools risks not only privacy but also national security and public trust.

As the UK government decides its next step, other nations will watch closely. The challenge is balancing technological progress with democratic accountability. This story is less about Palantir’s tech and more about who controls the digital future of public health.